Early detection of cancer through organized screening is a central component of population-level strategies to reduce cancer mortality. For screening programs to be effective, it is important that those invited to screening participate. However, uptake rates are suboptimal in many populations and vary between screening programs, indicating a complex combination of patient factors that require elucidation to develop evidence-based strategies to increase participation. In this review, the authors summarize individual-level (sociodemographic and psychosocial) factors associated with cancer screening uptake and evidence for the effectiveness of behavioral interventions to increase uptake. The authors reflect on current trends and future directions for behavioral cancer screening research to overcome challenges and address unmet needs in reducing cancer mortality.

Keywords: behavioral intervention • cancer screening • message framing • patient factors • screening uptake • socioeconomic status

The worldwide cancer burden is growing rapidly against the background of an aging population. In 2020, there were an estimated 19.3 million new cancer cases and 10 million cancer deaths globally, and it is estimated that annual cancer cases will increase to 28.4 million by 2040 if current trends continue [1]. Diagnosis of cancer at an early stage is crucial to reducing cancer mortality rates. Many countries have set targets to drive for earlier and faster cancer diagnosis. For example, in England the National Health Service set the goal that the proportion of people with cancer diagnosed at an early stage will increase from approximately 50–75% by 2028 [2].

Early detection of cancer and precancer through screening of asymptomatic people forms a key part of any national cancer strategy. There is high-quality evidence from randomized controlled trials that organized screening is effective at reducing cancer mortality [3–6]. Consequently, there are established national screening programs for breast, cervical and colorectal cancer in many countries. Screening for lung cancer is currently under expansion internationally, and screening for prostate cancer is available but not recommended as an organized program.

Organized cancer screening has been implemented in most European countries, North America, Australia and parts of Asia but is less common in low- and middle-income countries, including those in Central and South America, Africa and the Eastern Mediterranean region.

In this review, the authors examine patient factors in cancer screening uptake, summarizing evidence known to the authors combined with evidence identified through ad hoc ‘scoping’ searches to fill gaps and update our knowledge. The authors highlight key defining developments, relying generally on the interpretation of the authors of the original research. The authors include some evidence of prostate cancer screening uptake because it may be relevant to other cancer screening programs, such as with regard to understanding engagement of men in colorectal and lung cancer screening.

The authors focus primarily on evidence from the UK and US, supplemented by evidence originating from other countries with organized cancer screening. The UK and US have generated much of the relevant research into patient factors in cancer screening, indicating potential shortcomings of the generalizability of current knowledge to screening uptake globally and the need for more research in different cultures and health systems. Although country-specific nuances of screening programs and their organization can make it difficult to transfer lessons learned in one country to another, inclusion of evidence from both the UK and US offers insight into patient
factors in cancer screening within two contrasting healthcare systems. Cancer screening in the UK is free at the point of delivery, supported by the UK National Screening Committee, and includes systematic call and recall of eligible patients based on their registration with a general practitioner. By contrast, there is no centrally organized cancer screening in the US, but patients can self-refer and discuss screening with their doctor via health insurance or government-run health programs. Current US Preventive Services Task Force and UK National Screening Committee cancer screening recommendations are shown in Table 1.

Uptake is typically defined as the percentage of those invited who receive an adequate screen (a definitive test result) within a specified period after their test. Uptake has been described as the most important factor in determining the success of a cancer screening program [17]. There are several reasons why participation in cancer screening should be high. First, high uptake ensures that an adequate number of cancers are detected early, with a significant enough reduction in cancer-specific mortality to make the program cost-effective. Second, there are disparities in uptake between different sociodemographic groups, which means that low uptake of screening could contribute to widening inequalities in cancer survival. Third, those most at risk of cancer may be least likely to be screened – an example of the ‘inverse care law’ [18] – potentially compromising the effectiveness of screening.

The benefits of a cancer screening program should outweigh the harms. Potential benefits include a reduction in cancer-specific mortality, reduced health service costs, greater awareness of the disease and its symptoms and emotional reassurance. Potential harms can include diagnosis of a cancer that would not have caused a problem during the patient’s lifetime (‘overdiagnosis’), false-positive results and unnecessary treatment leading to greater costs, associated risks and complications of diagnostic procedures and emotional distress to the patient. It is not the goal simply to achieve greater uptake but to achieve uptake based on informed decisions that involve understanding and consideration of the potential costs and benefits of taking part in screening [19]. This requires the provision of information explaining the potential consequences in a way that can be understood so that an autonomous and informed decision can be made that is consistent with individual values and beliefs [20]. Cancer screening participation should therefore be a personal choice and not a directive from an authority.

Data from the National Health Interview Survey in the US indicate that uptake of cancer screening varies according to cancer type: 81.3% for cervical screening, 71.7% for breast screening and 63.4% for colorectal screening [21]. Uptake of National Health Service cancer screening programs in England is 72.2% for cervical screening [22], 69.1% for breast screening [23] and 57.9% for colorectal screening [24]. Variations in uptake between cancer screening programs highlight the challenges of understanding barriers to screening that may vary across screening programs, each of which utilizes a different screening method and targets a distinct ‘at-risk’ population group (Table 1).

Table 1. US Preventive Services Task Force and UK National Screening Committee cancer screening recommendations.

| Cancer Type                  | USPSTF Recommendations                                                                 | UK NSC Recommendations                                                                 | Ref. |
|------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|------|
| Breast cancer screening      | Women aged 50–74 years get a mammogram every 2 years. Women aged 40–49 years may start screening subject to individual values and preferences. | Women aged 50–70 years get a mammogram every 3 years. Women aged 71 years and over can self-refer to continue screening. | [7,8]|
| Cervical cancer screening    | Recommended in women aged 21–29 years every 3 years with cervical cytology alone and in women aged 30–65 years every 3 years with cervical cytology alone, every 5 years with high-risk HPV testing alone or every 5 years with HPV testing in combination with cytology (co-testing). | Women aged 25–64 years get HPV primary screening; every 3 years for ages 25–49, then every 5 years until the age of 64. | [9,10]|
| Colorectal cancer screening  | Women and men aged 45–75 should be regularly screened. Several screening strategies, including stool tests, flexible sigmoidoscopy, colonoscopy and CT colonography (virtual colonoscopy), are recommended. Adults aged 76–85 years should be selectively offered screening. | Women and men aged 60–74 years (50–74 years in Scotland) get a FIT every 2 years (FOBT in Northern Ireland). | [11,12]|
| Lung cancer screening        | Women and men aged 50–80 years with a 20 pack-year smoking history and who currently smoke or have quit within the past 15 years get a low-dose CT scan annually. | Not recommended (under review). | [13,14]|
| Prostate cancer screening    | Not recommended, but men aged 55–69 years can get a PSA test after individualized discussion of the benefits and risks. | Not recommended; however, men over 50 can get a PSA test but should consider the benefits and risks. | [15,16]|

CT: Computed tomography; FIT: Fecal immunochemical test; FOBT: Fecal occult blood test; PSA: Prostate-specific antigen; UK NSC: UK National Screening Committee; USPSTF: US Preventive Services Task Force.
Table 2. Overview of patient factors examined in relation to uptake of cancer screening.

| Sociodemographic factors | Capability factors | Motivational factors | Opportunity factors |
|--------------------------|--------------------|----------------------|---------------------|
| Sex                      | Knowledge          | Emotions             | Social norms and stigma |
| Age                      | Mental and physical capability | Habits              | Environment and resources |
| Socioeconomic status     | Health literacy    | Attitudes and beliefs | Perceived efficacy and response efficacy |
| Race/ethnicity           |                    |                      | Perceived risk      |
|                          |                    |                      | Intentions          |

Screening modalities can change over time; for example, the guaiac fecal occult blood test (FOBT) for colorectal screening has been replaced in many countries by the simpler to use fecal immunochemical test (FIT), whereas more invasive flexible sigmoidoscopy and colonoscopy methods are also in use as a primary screening tool in some countries. Eligibility guidelines for screening are also regularly reviewed; for example, a proposed age extension to National Health Service breast cancer screening is currently being trialed [25]. Despite such developments, much of the previous research into patient factors and the various influences on screening behavior remains relevant to current screening strategies.

To reduce cancer mortality, there is a need to understand patient factors associated with cancer screening uptake (including sociodemographic characteristics such as age and psychosocial factors such as perceived risk of cancer) and to draw on behavioral science to inform interventions to promote greater engagement with screening programs. It is acknowledged that patient factors represent only one component of the multilevel influences on screening behavior [26], but they are central to increasing uptake of cancer screening.

This review aims to narratively summarize evidence of the association between patient factors and cancer screening participation, describe advances in behavioral strategies to promote uptake and consider current and future challenges in the field of cancer screening behavior. The authors consider the role of sociodemographic and psychosocial factors, including those that contribute to an individual’s capability, motivation and opportunity to engage in cancer screening. Similarly, the authors consider interventions that operate at the individual level via a range of behavioral mechanisms. Considerations for future directions in the field include developments in cancer screening that could significantly impact patient engagement. This review gives a broad overview of the association between patient factors and cancer screening uptake along with intervention approaches that have been evaluated for their effectiveness at promoting uptake. Although the authors do not systematically present comparable quantitative data for these associations and effects, the overview facilitates consideration of knowledge gaps and future directions that should be addressed through the further collection of such data in future research.

Patient factors associated with uptake of cancer screening

Patient factors summarized in this review, with psychosocial factors organized by the ‘capability,’ ‘opportunity’ and ‘motivation’ system (COM-B) [27], are shown in Table 2.

Sociodemographic factors

Sex

Uptake of colorectal cancer screening in the UK is consistently higher in women than men [24,28,29], and women report slightly higher uptake than men in the US [21]. Men are less likely than women to adhere to three annual colorectal screens in Australia [30]. However, the relationship between sex and colorectal cancer screening uptake can depend on the screening modality and context [31]. A pilot study comparing FIT testing with FOBT in England observed a greater increase in uptake of FIT in men than women, reducing the absolute difference from 5.7 to 3.6% [32].

Uptake of lung cancer screening may be lower in women than men, but much of this evidence originates from trial contexts and so is not necessarily representative of the general screen-eligible population [33]. In the US, where uptake of lung cancer screening has been very low (~18%) since it was recommended, there are no differences between men and women in uptake [34,35] or in returning for a second annual screen [36]. Overall, differences between the sexes are small, and there are likely to be other more important factors influencing cancer screening uptake.
**Age**

Uptake of breast cancer screening increases with age in both the UK and US. For example, in England in 2018–2019, there was a 68.2% uptake of breast cancer screening in women aged 50–52 years, increasing to 73.2% in those aged 65–70 years [23]. This gradient is supported by data that include those invited as part of the age extension trial, with only 66.5% uptake in women aged 45–49 years. Age differences in breast cancer screening participation in the US are smaller than in the UK. The participation of women aged 65–74 years is slightly greater than that seen in those aged 50–64 years (72.2 vs 71.3%) [37]. Uptake of colorectal cancer screening is also higher in older age groups [38], a trend observed particularly in men [28].

There is a more complex association between age and cervical screening, reflecting the broader age range targeted. Coverage (the percentage of the eligible population screened adequately within a specified period) in England increases with age from the 25–29 to 50–54 age groups but then declines in older groups [22]. In the US, uptake peaks in the 30–39 age group [39]. Evidence from the research context suggests adherence to lung cancer screening is higher in the 60–74 age group than in younger and older age groups [36]. The relationship is less clear within implemented screening in the US, where two analyses found no difference in uptake by age [34,40] and one found greater uptake in the 65–80 age group than the 55–64 age group (16.5 vs 12.4%) [35]. There appears to be no difference in lung cancer screening uptake by age in pilot UK programs [41].

**Socioeconomic status**

There is a well-established socioeconomic gradient associated with cancer screening uptake. Colorectal cancer screening uptake is consistently lower in areas of greater deprivation in England [28,29,42], and women living in more socioeconomically deprived areas are less likely to attend breast, cervical and colorectal cancer screening [43,44] and to have ever been screened for these three cancers [45]. The association between greater deprivation and lower uptake was stronger for breast and colorectal screening than cervical screening in a study of women in Scotland [44]. In the US, higher education, higher income and health insurance are associated with greater likelihood of recent breast, cervical and colorectal cancer screening [21,39,46,47], although the gradient is less evident for income and cervical screening [21]. Lower uptake of colorectal screening has been observed in more disadvantaged groups in other countries, including Italy and South Korea [48]. Participation in lung cancer screening in the US is higher in those with a high school education than those without, reinforcing the importance of socioeconomic status markers in cancer screening uptake [47]. However, those with more than a high school education are also less likely to have been screened, an anomaly compared with other types of cancer screening, and time will tell if this association persists as lung screening becomes more established.

**Race/ethnicity**

Lower uptake of cancer screening has been consistently observed in nonwhite ethnic groups. In the UK, there is good evidence that uptake of all three of the main cancer screening programs is lower in more ethnically diverse areas [29,49,50], especially in South Asians [50–53]. In the US, non-Hispanic Black women have higher mammography coverage than white women (69.7 vs 65.8%), whereas other ethnic groups all have lower coverage (e.g., 60.9% in Hispanic women) [57]. A review of ethnic group participation in FOBT colorectal cancer screening programs found that there were minimal available data from countries other than the UK, preventing conclusions from being drawn [48]. US data show that African American/Black women have higher uptake of cervical screening (74.6%) than white (68.4%) or Hispanic/Latina women (68.6%) [54]. Aboriginal and Torres Strait Islander communities in Australia are less likely to engage in cancer screening than non-Indigenous groups (e.g., 34 vs 56% for cervical screening) [55,56]. In a meta-analysis, white participants were more likely to attend lung cancer screening compared with nonwhites [36]. Disparities between ethnic groups may be influenced by factors associated with minority group status, such as language and cultural barriers. For example, uptake of breast cancer screening in Norway was found to be 53.1% in immigrants versus 76.1% in nonimmigrants [57]. The Norway data showed that the difference reduced with increased duration of residency, suggesting that barriers are linked to assimilation to the country.

**Capability factors**

**Knowledge**

Lack of knowledge of cancer and screening is an important barrier to screening participation [58]. Awareness of the existence of cancer screening programs has generally been found to be high, especially for longer established
Nevertheless, there can be misconceptions in the general public about the purpose of cancer screening or about the necessity of screening in the absence of cancer symptoms. Avoidance of cancer risk information was associated with lower participation in colorectal cancer screening in a nationally representative US sample. Knowledge was lower in several minority ethnic groups compared with a white sample in England, and knowledge deficits may be associated with language barriers. A population-based survey in England found knowledge regarding the purpose of breast and FOBT screening, but not cervical or flexible sigmoidoscopy screening, to be lower in ethnic minority groups and lower social grades and higher in previous screening participants. Knowledge about the benefits and harms of screening is essential for informed uptake; however, screening invitations can lack the information necessary to promote knowledge and informed choice, and it is unclear to what extent screening participants understand the information they are given.

Mental & physical capability

Individuals with a learning disability are less likely than other people to attend cancer screening. In Scotland, women with learning disabilities were found to have lower levels of participation in all three cancer screening programs. In the same study, women with depression or greater multimorbidity were less likely to participate in colorectal and breast but not cervical cancer screening. Individuals with psychosis or more severe mental health problems have particularly low uptake of cancer screening. Better self-rated health was associated with colorectal cancer screening participation in England and significantly mediated the relationship between socioeconomic status and uptake. Some patients do not attend screening because they are already undergoing treatment for the cancer of interest or have other medical reasons that would make participation inappropriate.

Health literacy

Lower health literacy, numeracy and cognitive ability are associated with lower uptake of cancer screening. Studies have demonstrated that better health literacy is associated with greater screening knowledge, lower cancer fatalism (the belief that death is inevitable when cancer is present) and a more positive attitude toward screening, so it is likely that low health literacy and numeracy are also a significant barrier to informed uptake of cancer screening.

Motivational factors

Emotions

Theories that explain protective health behavior often provide a greater role for negative emotions, such as worry and fear, than positive emotions. Cancer worry is a motivator for breast, cervical and colorectal cancer screening, although moderate levels of worry appear more motivating than low or high levels. Fear may be an important factor in cancer screening in general and has been shown to have a complex relationship with uptake, operating as both a barrier and a facilitator. For example, fear, worry and disgust are more prevalent in groups least likely to participate in cancer screening, whereas fear of cancer in the absence of screening can motivate screening attendance. Other sources of fear as a barrier can include screening invitations, screening methods and the prospect of abnormal test results. Fear of potential embarrassment, discomfort or pain is a barrier to breast, cervical and colorectal screening. Greater disgust, such as that associated with handling stool samples, is a predictor of colorectal cancer screening avoidance. The evidence overall suggests that emotions are associated with uptake, but different aspects of emotions can impact on decision and action processes.

Habits

Research in a wide range of contexts has consistently found that past behavior is the best predictor of future behavior. It is unsurprising, then, that past screening attendance is the largest single predictor of future attendance and those who participate in one cancer screening program are significantly more likely to participate in others. This suggests, given the different levels of uptake observed, that there are barriers that are common across screening programs and others that are unique. Promoting first-time participation may be key to improving uptake in nonattenders.

Attitudes & beliefs

Despite its potential risks, most individuals report enthusiasm for cancer screening. It is unclear to what extent attitudes are influenced by information about benefits and harms of screening. For example, positive attitudes
toward cancer screening are observed even where individuals have been presented with information about potential harms [69]. Women who had previously received a false-positive mammography result were slightly more tolerant of the associated harm than other women [96]. 'Popularity paradox' is a term used to describe the increased likelihood for those who have been misdiagnosed and overtreated as a result of screening to believe that they owe their health to screening [97]. This evidence indicates that attitudes are resistant to information about the risks of screening and that people do not necessarily make informed decisions about screening attendance via a deliberative assessment of the risks and benefits.

Cancer fatalism is associated with nonuptake of breast, cervical and colorectal cancer screening both in the UK and the US [74,98]. Dislike of the screening test appears to be a stronger barrier to colorectal cancer screening than breast or cervical screening [45], further highlighting concerns around the practicalities and cleanliness of the test method. Altruistic reasons for attending cancer screening have been reported, underpinned by beliefs that screening is a good use of health service resources [64,99] and is a form of medical research that can advance science [100].

**Perceived efficacy & response efficacy**

Higher efficacy beliefs about cancer screening were associated with greater uptake of colorectal cancer screening in a sample of adults aged 60–69 in England but did not mediate the relationship between socioeconomic status and uptake [74]. Perceived efficacy of mammography was surveyed among women in the US, UK, Italy and Switzerland, with overestimations of effectiveness observed in all four countries and a greater number of accurate estimates negatively associated with being screened in the previous 2 years [101]. Self-efficacy to participate in colorectal cancer screening was associated with lower health literacy in a UK study [102]. Self-efficacy mediated the relationship between South Asian ethnicity and lower uptake in regions of England and Scotland [103].

**Perceived risk**

Risk perceptions are known to be an important factor in preventative health behavior but are difficult to measure, limiting understanding of the relationship with screening uptake. Perceptions of greater cancer risk are associated with participation in breast [104] and colorectal cancer screening [64], but individuals can have an optimistic bias about their cancer risk [105]. Qualitative research has found that there are benchmarks, or 'candidates,' against which people measure their personal risk, which influences screening attendance decisions [106,107]. Risk perceptions can be closely related to illness beliefs, such as the perceived severity of cancer, and known risk factors, such as family history of cancer and tobacco use, and can generate an emotional response, or 'affective risk perception' [108]. Risk perceptions may be only weakly associated with objective cancer risk factors. There is a need to improve the understanding of the nature and impact of risk perceptions through further research.

**Intentions**

A proportion of people who are motivated to attend screening and intend to take part fail to do so. This gap between intentions and behavior is well recognized in health psychology and may account for more than half of screening nonattendance [109]. This could be due to a range of factors, but research has found that having to book an appointment can be a barrier, especially in people without language proficiency [110], and that many people report putting off or forgetting to take part [64]. This suggests that interventions that aim to promote the translation of intentions into action could be effective at increasing screening attendance in those who are motivated to attend.

**Opportunity factors**

**Social norms & stigma**

Perceived norms have been shown to predict intentions to be screened for breast, colorectal and prostate cancer in the US [111]. A survey in England found that cancer stigma was associated with irregular or nonparticipation in all three national screening programs and was higher in men and in those from ethnic minority backgrounds [112]. Cervical screening can carry greater stigma for some cultural groups, such as those in which cancer is a taboo subject, exposing one's body to a stranger is forbidden or cervical cancer is associated with promiscuity [86]. Stigma associated with cancer as a perceived self-inflicted disease has been identified as a barrier to lung cancer screening [113]. This may be a factor in why smokers in the US display less willingness to consider lung cancer screening compared with never-smokers [114], whereas smokers in the UK are less likely to attend colorectal screening [80].
**Environment & resources**

An individual’s environment and resources can be important influences on cancer screening uptake. People living in urban locations may be less likely to attend in the UK, whereas the opposite has been observed in the US [47,115]. This may reflect the geographic spread of deprivation in the respective countries, combined with a greater distance barrier in rural US areas. Other practical barriers to cancer screening can include difficulty making an appointment and dependency on others to carry out activities of daily living [81,92]. Low social support is associated with nonattendance [116], and being unmarried is another commonly reported factor [31,88]. Colorectal cancer screening is often offered as a home test kit away from a medical setting, which can be perceived as a barrier to participation [93,99]. It is probable that a proportion of screening nonattenders do not receive the invitation [117], perhaps because they have moved to a different address.

In summary, there are a range of psychosocial factors that play a role in cancer screening uptake and some evidence regarding how they explain the influence of established sociodemographic factors. The socioeconomic gradient in uptake may be explained by more deprived groups experiencing more barriers to screening, such as lower health literacy and knowledge, greater cancer fatalism and greater perceived cancer stigma [74,84,118]. Psychosocial factors tend to predict screening intention better than they predict behavior, and sociodemographic factors may also have an influence by contributing to the intention–behavior gap [119]. This knowledge has informed the development and targeting of behavioral interventions, incorporating behavioral theory to promote cancer screening uptake.

**Behavioral interventions to increase cancer screening uptake**

Individual-level behavioral interventions aim to target mechanisms of cancer screening participation through environmental restructuring, information design or planning support and have been evaluated with randomized controlled trials and evidence syntheses.

**Environmental restructuring**

**Reminders**

Screening invitation reminders are an effective strategy for increasing uptake. They can be delivered by post, telephone or text message, all of which have been shown to increase uptake. In England, a postal reminder 1 week before a scheduled breast cancer screening appointment achieved uptake of 75% compared with 72% in the control group [120], whereas a text message reminder 48 h before an appointment for first-time invitees was associated with 64% uptake compared with 59% in the control group [121]. In Sweden, a postal reminder for women who did not respond to a first invitation increased cervical screening uptake by 9% in absolute terms compared to no postal reminder. In a group who had still not responded, a subsequent telephone reminder increased uptake to a level 31% higher than without a telephone reminder [122]. Text message reminders did not impact overall uptake of colorectal screening in England, although messages significantly increased uptake in first-time invitees compared with a control group (40.5 vs 34.9%) [123]. A systematic review concluded that text messaging interventions moderately increase uptake of breast and cervical cancer screening and may have a small effect on colorectal cancer screening [124]. Advance notification letters that are sent before a screening kit can improve rates of colorectal cancer kit return [125] but are ineffective at promoting cervical screening self-sampling kit return in the UK [126]. Adherence to lung cancer screening was increased with reminders in a systematic review of international studies [36]. Targeted reminders have also been evaluated. For example, a reminder letter that restated the invitation to colorectal cancer screening was sent to individuals who had not responded to the first invitation; it increased uptake overall and was more effective in the most deprived than the least deprived areas [127]. A meta-analysis of electronic physician and primary care provider prompts in ambulatory settings to recommend screening for nonattenders found they increased uptake of breast and colorectal cancer screening but not cervical screening [128]. Reminders can reduce the risk of forgetting and can be a cue for patients to form intentions to attend by planning how they are going to do so. Reminders may be an effective strategy for minimizing inequalities in cancer screening [129], as they appear to be particularly effective in first-time invitees and areas of greater deprivation.

**Fixed & flexible appointments**

Individuals have a strong tendency to behave according to the default or preset option, as it is usually easier to do so. Screening programs have harnessed the power of a default option by providing a fixed appointment time on invitations, a technique that has been found to increase uptake of breast and cervical screening compared with an
open invitation [92,130]. A second timed appointment has also been found to be effective when sending reminders to people who did not attend their first breast cancer screening appointment [131]. This strategy reduces the planning burden on the invitee; however, it should be implemented carefully to avoid inefficiency and waste as a result of missed appointments. There is a need for home screening kits, such as FIT and HPV self-sampling, to incorporate goal-setting and planning techniques to avoid the ‘easier’ option of delay and nonresponse. Flexible appointments can also improve uptake; for example, the option to change an office hour breast cancer screening appointment to an evening or weekend appointment was associated with an absolute increase in uptake of 2.8%, with 7% choosing the out-of-hours option [132].

**Modifications to screening test**

Modifications to the screening test itself can improve acceptability, usability and convenience. For example, using FIT rather than FOBT for colorectal cancer screening, which requires fewer stool samples, was associated with greater perceived ease of completion and lower disgust than FOBT [133] and an increase in uptake in Scotland from 56.2 to 64.1%, with a greater increase in people from more deprived areas (Figure 1) [134]. The HPV self-sampling test has been found to have high acceptability [135] and to significantly improve uptake [126] compared with clinician sampling, creating an opportunity to engage those who do not participate in traditional cervical screening.

**Publicity & mass media**

Mass media campaigns can lead to increases in cancer screening uptake in areas where there is good availability of organized screening [136]. Such campaigns can seek to provide information about screening, modify beliefs, address concerns and model screening attendance. For example, television advertisement campaigns in Australia were associated with an 18% increase in cervical screening [137] and an 11% increase in colorectal cancer screening kit return, with a significantly greater impact in those who had never previously participated [138]. Furthermore, media coverage of high-profile cancer deaths can be associated with increases in screening uptake [139].

**Social support**

Interventions targeting social support, such as tailored counseling about screening, produced stronger effects on colorectal cancer screening uptake than other intervention techniques in a meta-analysis [140]. The same study also found that interventions delivered in the community were more effective than those delivered in a primary care context, indicating the importance of individuals’ social environment in promoting uptake.
Information design
Strategies to modify screening information aim to improve knowledge and understanding of screening, reduce negative attitudes or improve self-efficacy to successfully participate in screening.

Content modification
Materials that addressed known barriers to colorectal cancer screening were found to reduce negative attitudes, promote anticipation of a positive screening experience and increase attendance by 3.6% compared with standard materials [141]. An enhanced procedural leaflet increased colorectal cancer screening participation by 6% [142]. However, a supplementary leaflet containing simplified summaries of key information and a narrative leaflet containing personal screening stories designed to improve comprehension in people with low literacy and/or numeracy were ineffective at improving uptake both overall and in lower socioeconomic groups [127]. Redesign of written information may have limited ability to improve uptake, especially where literacy is low. A US study evaluated brief education delivered by a clinic-based research assistant, including demonstration of how to complete the FOBT kit, in a sample in which the majority had low literacy and found that 11.4% returned all three subsequent annual kits compared with 4.7% without the education [143]. Another group in the study received more intensive support from a clinic nurse, including telephone contact and problem-solving, resulting in greater uptake (13.6%). This demonstrates the potential for personal support to promote uptake without reliance on written materials, although uptake is still low and such support requires significantly greater resources. Other evidence-based health communication methods should be explored, such as the use of illustrations and social media techniques [144,145].

Primary care endorsement
An endorsement letter from a patient’s general practitioner can increase uptake of colorectal screening [127,142,146,147], breast cancer screening [148,149] and cervical screening [150,151]. This provides a recommendation from a trusted source with which patients have an existing relationship, carrying ‘source credibility.’ This may be particularly effective for colorectal cancer screening because it does not normally involve contact with a healthcare professional. It may also be effective for some underserved cultural groups, although this approach could conflict with the goal of informed choice, with evidence that screening invitations can be viewed as an instruction to be obeyed in cultures where the doctor is highly revered and seen as the sole decision maker about health [67,110].

Message framing
Framing screening messages using social comparison via descriptive social norms (highlighting what is commonly done) may have more impact than injunctive norms (highlighting what others approve of) [111]. However, injunctive norms could limit the risk of ‘reactance’ and unintended consequences of descriptive norms. The effects of subjective norms on prostate cancer screening participation in African Americans are stronger in those with greater racial identity [152], highlighting a potential strategy for promoting uptake in underserved groups with a shared identity. Loss-framed messages, where individuals are prompted to think of the negative consequences of not attending screening, may be slightly more effective than gain-framed messages at increasing intentions to be screened for breast cancer [153]. Similar findings were noted in a study on colorectal cancer screening [154]. The authors of this study found, however, that in the gain-framed condition an accompanying ‘affective booster’ – for example, an opportunity to anticipate and feel relief at receiving a negative test – increased message persuasiveness. A theory-based intervention that aimed to promote uptake through anticipated regret via a questionnaire delivered with prenotification letters found no impact on uptake on colorectal cancer screening participation, although there was higher uptake in those with low intention to participate [155]. A similar intervention reported greater uptake of cervical screening in those who were definitely exposed to the anticipated regret messages [156]. Such approaches target automatic and affective decision-making rather than rational and reflective cognitive decision-making and as such can raise questions about whether they facilitate autonomous and informed decisions. There is a need to assess the impact of information design strategies on comprehension of information and decisions that are consistent with one’s values as well as the effect on uptake.

Planning support
Interventions to support individuals in making specific plans about screening participation aim to reduce the intention–behavior gap. They seek to achieve this through goal setting and action planning (e.g., making if-then plans, or implementation intentions). The evidence of effectiveness is mixed, however; for example, a colorectal
cancer screening information leaflet with three preformulated implementation intentions was not effective at improving uptake [157]. Women who were asked in a study to complete three implementation intentions about attending breast cancer screening were no more likely to attend than controls, but this was partly explained by the failure of some to write down their plans [158]. Existing motivation or intention to participate in screening and engagement with the support tool are among the factors that may determine the effectiveness of planning interventions [159], so it is important that users are involved in their development and design. Attending a screening appointment requires a different type of action than completing and returning a postal test kit. The former involves time, travel and a social situation, whereas the latter involves greater personal control about where and when screening takes place. Planning support tools are known to be effective at promoting a range of other health behaviors [160], suggesting a need to further explore their utility in cancer screening contexts.

In this review, the authors have summarized evidence of individual-level behavioral interventions that seek to restructure the individual’s environment, modify information design and support planning. The effectiveness of interventions is likely to be improved through the use of multifaceted approaches that combine reminders, simplified information and tests that are easy to undertake [161]. A theoretically guided approach to intervention design improves the understanding of how and why interventions achieve their effects, and interventions at multiple levels (e.g., provider and patient level) may have greater potential to improve cancer screening uptake [162].

**Conclusion**

There are sociodemographic and psychosocial factors known to be associated with cancer screening uptake. Some factors vary between screening programs, whereas others appear to be associated with cancer screening uptake in general. Such knowledge allows evidence-based interventions to be developed and evaluated. Behavioral support holds much potential for reducing cancer mortality through improved screening uptake, but it is important that intervention development builds on existing research and theory. There is a need to further simplify messages, reduce the effort required to participate in screening and support people in planning their participation and their response to barriers. Interventions shown to be effective, many of which are simple, low-cost approaches, should be universally implemented by screening providers.

**Future perspective**

There is growing interest in whether variations in individual cancer risk and the potential to benefit from cancer screening could be used to improve the efficiency of cancer screening programs and reduce associated harms. This represents a shift to a risk-stratified screening approach, targeting screening to those with higher cancer risk and screening those at low risk less frequently or not at all. There are already efforts to introduce risk stratification into national breast cancer screening programs. A 2019 independent review of screening in England recommended that targeted screening should have equal weight to population screening and that there should be a single advisory body covering both types of programs [163]. In addition, risk prediction models for lung cancer screening are under evaluation to optimize criteria used to select eligible patients [164] using multivariate models rather than only age and smoking history, as currently recommended in the US. Behavioral science can provide evidence-based approaches to personalized risk communication. There may be greater opportunity to promote engagement using tailored screening information to address individual beliefs and concerns alongside a tailored risk approach. Public attitudes, beliefs, risk perceptions and emotions should also be explored in the context of risk-stratified screening to ensure that such strategies do not exacerbate existing inequalities in screening uptake.

With the development of new technologies and improvements in the understanding of genomics and the cellular characteristics of cancer, other approaches to risk stratification have focused on genetic tests or simple biomarker tests [165]. Biomarker tests include analysis of samples of saliva, exhaled breath, urine and blood for potentially multiple cancers in one test. These tests might be more effective and less harmful at detecting early cancer than existing tests by being quicker and cheaper to perform and allowing the targeting of imaging to those at greater risk. Novel screening methods may better detect at a treatable stage cancers that cannot be effectively detected through population screening using currently available modalities alone, such as ovarian, liver and pancreatic cancer. Such developments raise questions about patient factors in cancer screening. For example, what will be the acceptability and perceived efficacy of a blood test to detect lung cancer? How can individuals be supported to understand and make informed decisions about an increasing number of screening tests with different attributes and associated potential harms? Behavioral science can seek to address these questions and develop evidence-based interventions to inform and promote uptake, which may be key to the success of a cancer screening program offering a novel test.
With the development of new tests and a potential increase in cancer screening activity in many countries, more people may be at risk of screening harm through overdiagnosis. It is vital that public understanding of overdiagnosis is improved and the ‘popularity paradox’ prevented. This is a prerequisite to informed decision-making about cancer screening participation but may be challenging to achieve and should draw on evidence-based health communication methods. Greater awareness of screening harms, accompanied by awareness that the screening program is effective at reducing the cancer burden provided that individuals participate, does not have to result in lower uptake. In the pursuit of greater uptake alongside informed uptake, there is a need for behavioral interventions that prioritize patient autonomy. This may involve a shift toward behavioral techniques that seek to educate rather than manipulate and support people to act in accordance with their values and intentions. Decision aids can be used to facilitate screening decision-making that is consistent with a patient’s values, priorities and attitudes toward risk. Decision aids have been associated with lower uptake, however, when evaluated for breast and colorectal cancer screening [166,167]. A risk-based approach may necessitate an acceptance that better informed decisions may result in lower overall uptake, particularly where there is uncertainty about the balance of benefits and risks for an individual.

The roll-out of lung cancer screening requires special consideration because of the distinct ‘at-risk’ group who will be invited, consisting predominantly of individuals with a substantial smoking history. Public knowledge of the cancer risk associated with smoking is high, which may increase perceptions of risk and cancer fear in those eligible for screening. Behavioral theory tells us that, in the absence of high self-efficacy to undertake screening, high cancer fear may lead to screening avoidance rather than attendance [168]. American Thoracic Society recommendations to engage high-risk groups include the use of patient navigators to serve as outreach workers and help the most vulnerable overcome barriers, shared decision-making tools that are suitable for low literacy and numeracy levels and for different cultural backgrounds and the use of telehealth and mobile screening units to overcome geographic barriers [169]. Media such as letters and leaflets are also recommended and were associated with uptake of 53% in a UK sample of predominantly smokers living in areas of greater deprivation [170]. There is also a risk of smokers receiving false reassurance from negative screening results, forming a potential unintended harm of lung cancer screening via reduced motivation to quit smoking [171]. As lung cancer screening becomes more commonplace, patient factors should be carefully monitored and appropriate behavioral interventions developed, such as smoking cessation support tailored to individual screening experiences.

Inequalities in uptake between the highest and lowest levels of deprivation in England have significantly reduced for breast cancer screening but not for cervical screening, suggesting that efforts to reduce inequalities have had some success [172]. There is still a need to improve service design to overcome cultural and language barriers to increase trust and confidence in screening providers and improve uptake in underserved groups. Similarly, unique barriers experienced by groups, such as those living with a learning disability or a mental illness, should be addressed, an area where there is currently a lack of evidence about appropriate behavioral support [173]. The need for informed choice means that screening information should explain clearly the possible benefits and harms, but this assumes that people make rational decisions, when the evidence in this review suggests that automatic motivation (e.g., emotions, habits) is an important determinant of screening participation. Nonresponders to screening invitations are usually very difficult to engage in research, often limiting the available evidence to influences of sociodemographic factors rather than psychosocial ones. Greater resources will be required to undertake research methods that can effectively engage nonresponders to better elucidate relationships between screening participation and different patient factors in underserved groups.

Financial & competing interests disclosure

This work was supported by a grant from Cancer Research UK (C9227/A27877). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.
Executive summary

Background
- There are established screening programs for breast, cervical, colorectal and lung cancer.
- Improving uptake of cancer screening is crucial to reducing cancer mortality.
- Variations in uptake between cancer screening programs highlight the importance of understanding patient factors.

Patient factors associated with uptake of cancer screening
- Women are more likely than men to take part in colorectal cancer screening.
- Older age is associated with greater uptake of breast and colorectal cancer screening.
- People with low socioeconomic status, low health literacy or learning disability and those from minority ethnic groups are less likely to participate in cancer screening.
- Knowledge, attitudes and beliefs about cancer and screening are important modifiable patient factors.
- Cancer fear and perceptions of cancer risk can be both motivators and barriers to screening.
- Motivated people who intend to take part in cancer screening often fail to do so.
- Cancer stigma is a barrier to screening, especially in smokers and some cultural groups.
- Practical barriers and a lack of social support are associated with nonattendance.

Behavioral interventions to increase cancer screening uptake
- Reminders are a well-researched behavioral strategy that can increase uptake.
- Fixed appointment times on invitations or reminders increase uptake of breast and cervical screening.
- Modifications to colorectal and cervical screening tests can improve acceptability, usability and convenience, leading to higher uptake.
- Mass media campaigns and high-profile cancer deaths can promote screening uptake.
- General practitioner endorsement is associated with greater uptake of colorectal, breast and cervical screening.
- Message framing and planning support are behavioral approaches in need of further research.

Future perspective
- Risk-stratified screening and expansion of lung cancer screening pose new challenges for behavioral research.
- Novel screening methods raise questions about the acceptability and perceived efficacy of tests.
- Public understanding of screening harms should be improved through evidence-based health communication.
- Lung cancer screening requires special consideration, and patient factors should be monitored and behavioral interventions developed.
- There is a need to further simplify messages, support planning and problem-solving and reduce the effort required to participate in cancer screening.
- Inequalities in screening uptake persist, and further efforts are required to ensure equitable access to cancer screening for all.

Open Access
This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
2. National Health Service Long Term Plan (2020). www.longtermplan.nhs.uk/publication/nhs-long-term-plan/
3. Ronco G, Dillner J, Elfström KM et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383(9916), 524–532 (2014).
4. Myers ER, Moorman P, Gierisch JM et al. Benefits and harms of breast cancer screening: a systematic review. JAMA 314(15), 1615–1634 (2015).
5. Aberle DR, Adams AM, Berg CD et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365(5), 395–409 (2011).
6. Lin JS, Perdue LA, Henrikson NB, Bean SI, Blasi PR. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 325(19), 1978–1998 (2021).
7. Siu AL. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 164(4), 279–296 (2016).
8. UK National Screening Committee. The UK NSC recommendation on breast cancer screening in women over 50 (2019). https://webarchive.nationalarchives.gov.uk/20210626053323/https://legacyscreening.phe.org.uk/breastcancer
9. US Preventive Services Task Force. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA 320(7), 674–686 (2018).

10. UK National Screening Committee. The UK NSC recommendation on cervical cancer screening in women (2019). https://webarchive.nationalarchives.gov.uk/ukgwa/20210626052855/https://legacyscreening.phe.org.uk/cervicalcancer

11. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 325(19), 1965–1977 (2021).

12. UK National Screening Committee. The UK NSC recommendation on bowel cancer screening in adults (2018). https://webarchive.nationalarchives.gov.uk/ukgwa/20210626072933/https://legacyscreening.phe.org.uk/bowelcancer

13. US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA 325(10), 962–970 (2021).

14. UK National Screening Committee. The UK NSC recommendation on lung cancer screening in adult cigarette smokers (2007). https://webarchive.nationalarchives.gov.uk/ukgwa/20210626053404/https://legacyscreening.phe.org.uk/lungcancer

15. US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 319(18), 1901–1913 (2018).

16. UK National Screening Committee. The UK NSC recommendation on prostate cancer screening/PSA testing in men over the age of 50 (2020). https://webarchive.nationalarchives.gov.uk/ukgwa/20210626073749/https://legacyscreening.phe.org.uk/prostatecancer

17. Weller DP, Campbell C. Uptake in cancer screening programmes: a priority in cancer control. Br. J. Cancer 101, S55–S59 (2009).

18. Hart JT. The inverse care law.

19. Rimer BK, Briss PA, Zeller PK, Chan EC, Woolf SH. Informed decision making: what is its role in cancer screening? Cancer 101(Suppl. 5), 1214–1228 (2004).

20. Jeppson RG, Hewison J, Thompson AGH, Weller D. How should we measure informed choice? The case of cancer screening. J. Med. Ethics 31(4), 192–196 (2005).

21. Hall IJ, Tangka FKL, Sabatino SA, Thompson TD, Graubard BI, Breen N. Patterns and trends in cancer screening in the United States. Prev. Chronic Dis. 15, e97 (2018).

22. National Health Service Digital. Cervical screening programme, England, 2019–20 (2020). https://digital.nhs.uk/data-and-information/publications/statistical/cervical-screening-annual/england---2019-20

23. National Health Service Digital. Breast Screening Programme, England, 2019–20 (2021). https://digital.nhs.uk/data-and-information/publications/statistical/breast-screening-programme/england---2019-20

24. Cancer Research UK. Bowel cancer screening coverage and uptake, UK, FY2012–2015 (2020). https://webarchive.nationalarchives.gov.uk/ukgwa/20210626052855/https://legacyscreening.phe.org.uk/bowelcancer

25. Wools A, Dapper EA, Leeuw JRJD. Colorectal cancer screening participation: a systematic review. Int. J. Epidemiol. 26(10), 962–970 (2021).

26. Schütte S, Dietrich D, Montet X, Flahault A. Participation in lung cancer screening programs: are there gender and social differences? A systematic review. JAMA 319(18), 1901–1913 (2018).

27. Michie S, Van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement. Sci. 6, 42 (2011).

28. Jahangir SH, Atif S, Riaz A et al. Lung cancer screening uptake: a behavioral risk factor surveillance system analysis. Int. J. Prev. Med. 5(2), 250–255 (2019).

29. von Wagner C, Baio G, Raine R et al. Behavioural and demographic predictors of adherence to three consecutive faecal occult blood test screening opportunities: a population study. BMC Public Health 14(1), 238 (2014).

30. Moss S, Mathews C, Day TJ et al. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England. Gut 66(9), 1631–1644 (2017).

31. Hanley AJ, Grinyer A, Zhang J et al. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England. Gut 66(9), 1631–1644 (2017).

32. Scipio G, Maffi A, Mansfield A et al. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England. Gut 66(9), 1631–1644 (2017).

33. Scipio G, Maffi A, Mansfield A et al. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England. Gut 66(9), 1631–1644 (2017).

34. Lam ACL, Aggarwal R, Cheung S et al. Predictors of participant nonadherence in lung cancer screening programs: a systematic review and meta-analysis. Lung Cancer 146, 134–144 (2020).
37. CDC. Use of mammography among women aged 40 and over, by selected characteristics: United States, selected years 1987–2015 (2020). www.cdc.gov/nchs/data/hus/2017/070.pdf

38. Steele RJ, Kostourou I, Mccllements P et al. Effect of gender, age and deprivation on key performance indicators in a FOBT-based colorectal screening programme. J. Med. Screen. 17(2), 68–74 (2010).

39. American Cancer Society. Cancer prevention & early detection facts & figures 2019–2020 (2019). https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-prevention-and-early-detection-facts-and-figures/cancer-prevention-and-early-detection-facts-and-figures-2019-2020.pdf

40. Yong PC, Sigel K, Rehmami S, Wintoivesky J, Kale MS. Lung cancer screening uptake in the United States. Chest 157(1), 236–238 (2020).

41. Crosbie PA, Balata H, Evison M et al. Second round results from the Manchester ‘Lung Health Check’ community-based targeted lung cancer screening pilot. Thorax 74(7), 700–704 (2019).

42. Lo SH, Halloran S, Snowball J, Seaman H, Wardle J, Von Wagner C. Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme. Gut 64(2), 282–291 (2015).

43. Smith D, Thomson K, Bambr a C, Todd A. The breast cancer paradox: a systematic review of the association between area-level deprivation and breast cancer screening uptake in Europe. Cancer Epidemiol. 60, 77–85 (2019).

44. Mccowan C, Mckimming P, Papworth R et al. Comparing uptake across breast, cervical and bowel screening at an individual level: a retrospective cohort study. Br. J. Cancer 121(8), 710–714 (2019).

45. Lo SH, Waller J, Wardle J, Von Wagner C. Comparing barriers to colorectal cancer screening with barriers to breast and cervical screening: a population-based survey of screening-age women in Great Britain. J. Med. Screen. 20(2), 73–79 (2013).

46. Beydoun H, Beydoun M. Predictors of colorectal cancer screening behaviors among average-risk older adults in the United States. Cancer Causes Control 19(4), 339–359 (2008).

47. Henley SJ, Thomas CC, Lewis DR et al. Annual report to the nation on the status of cancer, part II: progress toward Healthy People 2020 objectives for 4 common cancers. Cancer 126(10), 2250–2266 (2020).

48. De Klerk C, Gupta S, Dekker E, Esink-Bo t M. Socioeconomic and ethnic inequities within organised colorectal cancer screening programmes worldwide. Gut 67(4), 679–687 (2018).

49. Bang JY, Yadegarifar G, Soljak M, Majeed A. Primary care factors associated with cervical screening coverage in England. J. Public Health (Oxf) 34(4), 532–538 (2012).

50. Bansal N, Bhopal RS, Steiner MFC, Brewster DH, Scottish H, Ethnicity Linkage S. Major ethnic group differences in breast cancer screening uptake in Scotland are not extinguished by adjustment for indices of geographical residence, area deprivation, long-term illness and education. Br. J. Cancer 106(8), 1361–1366 (2012).

51. Szczepura A, Price C, Gumber A. Breast and bowel cancer screening uptake patterns over 15 years for UK south Asian ethnic minority populations, corrected for differences in socio-demographic characteristics. BMC Public Health 8, 346 (2008).

52. Robb KA, Power E, Atkin W, Wardle J. Ethnic differences in participation in flexible sigmoidoscopy screening in the UK. J. Med. Screen. 15(3), 130–136 (2008).

53. Campbell C, Douglas A, Williams L et al. Are there ethnic and religious variations in uptake of bowel cancer screening? A retrospective cohort study among 1.7 million people in Scotland. BMJ Open 10(10), e037011 (2020).

54. National Center for Health Statistics. Use of Pap smears among women aged 18 and over, by selected characteristics: United States, selected years 1987–2015 (2018). https://www.cdc.gov/nchs/data/hus/2018/034.pdf

55. Tapia KA, Garvey G, Mcentee MF, Rickard M, Lydiard L, Brennan PC. Breast screening attendance of Aboriginal and Torres Strait Islander women in the Northern Territory of Australia. Aust. NZ J. Public Health 43(4), 334–339 (2019).

56. Whop LJ, Garvey G, Baade P et al. The first comprehensive report on Indigenous Australian women’s inequalities in cervical screening: a retrospective registry cohort study in Queensland, Australia (2000–2011). Cancer 122(10), 1560–1569 (2016).

57. Bharagava S, Tsuruda K, Moen K, Bukholm I, Hofvind S. Lower attendance rates in immigrant versus non-immigrant women in the Norwegian breast cancer screening programme. J. Med. Screen. 25(3), 155–161 (2017).

58. Bongaerts THG, Büchner FL, Middelkoop BJ, Guicherit OR, Nu mans ME. Determinants of (non-)attendance at the Dutch cancer screening programmes: a systematic review. J. Med. Screen. 27(3), 121–129 (2019).

59. Ford JS, Coup s EJ, Hay JL. Knowledge of colon cancer screening in a national probability sample in the United States. J. Health Commun. 11(Suppl. 1), 19–35 (2006).

60. Carrasco-Garrido P, Hernandez-Barrera V, Lopez De Andres A, Jimenez-Trujillo I, Gallardo Pino C, Jimenez-Garcia R. Awareness and uptake of colorectal, breast, cervical and prostate cancer screening tests in Spain. Eur. J. Public Health 24(2), 264–270 (2014).

61. Rakowski W, Meisner H, Vernon SW, Bren n N, Rimer B, Clark MA. Correlates of repeat and recent mammography for women ages 45 to 75 in the 2002 to 2003 Health Information National Trends Survey (HINTS 2003). Cancer Epidemiol. Biomarkers Prev. 15(11), 2093–2101 (2006).

62. Hawkins NA, Benard VB, Greek A, Roland KB, Manninen D, Saraiya M. Patient knowledge and beliefs as barriers to extending cervical cancer screening intervals in federally qualified health centers. Prev. Med. 57(5), 641–645 (2013).
90. Jones RM, Devers KJ, Kuzel AJ, Woolf SH. Patient-reported barriers to colorectal cancer screening: a mixed-methods analysis. *Am. J. Prev. Med.* 38(5), 508–516 (2010).

91. Davis M, Oaten M, Occhipinti S, Chambers S, Stevenson R. An investigation of the emotion of disgust as an affective barrier to intention to screen for colorectal cancer. *Eur. J. Cancer Care (Engl.)* 26(4), e12582 (2017).

92. Jepson R, Clegg A, Forbes C, Lewis R, Sowden A, Kleijnen J. The determinants of screening uptake and interventions for increasing uptake: a systematic review. *Health Technol. Assess.* 4(14), i–vii; 1–133 (2000).

93. Kotzur M, McCowan C, MacDonald S et al. Why colorectal screening fails to achieve the uptake rates of breast and cervical cancer screening: a comparative qualitative study. *BMJ Qual. Saf.* 29(6), 482–490 (2020).

94. Waller J, Osborne K, Wardle J. Enthusiasm for cancer screening in Great Britain: a general population survey. *Br. J. Cancer* 112(3), 562–566 (2015).

95. Schwartz LM, Woloshin S, Fowler FJ Jr., Welch HG. Enthusiasm for cancer screening in the United States. *JAMA* 291(1), 71–78 (2004).

96. Schwartz LM, Woloshin S, Sox HC, Fischhoff B, Welch HG. US women's attitudes to false positive mammography results and detection of ductal carcinoma in situ: cross sectional survey. *BMJ* 320(7250), 1635–1640 (2000).

97. Raffle AE, Mackie A, Gray JAM. *Screening: Evidence and Practice* (2nd Edition). Oxford University Press, Oxford, UK (2019).

98. Schueler KM, Chu PW, Smith-Bindman R. Factors associated with mammography utilization: a systematic quantitative review of the literature. *J. Womens Health* 17(9), 1477–1498 (2008).

99. Chapple A, Ziebland S, Hewitson P, Mcpherson A. What affects the uptake of screening for bowel cancer using a faecal occult blood test (FOBt): a qualitative study. *Soc. Sci. Med.* 66(12), 2425–2435 (2008).

100. Dharni N, Armstrong D, Chung-Faye G, Wright AJ. Factors influencing participation in colorectal cancer screening—a qualitative study in an ethnic and socio-economically diverse inner city population. *Health Expect.* 20(4), 608–617 (2016).

101. Domenighetti G, D'avanzo B, Egger M. *Cancer Stigma and Cancer Screening*. Oxford University Press, Oxford, UK (2019).

102. Orbell S, Szczepura A, Weller D, Gumber A, Hagger MS. South Asian ethnicity, socioeconomic status, and psychological mediators of faecal occult blood colorectal screening participation: a prospective test of a process model. *Health Psychol.* 36(12), 1161–1172 (2017).

103. Katapodi MC, Lee KA, Facione NC, Dodd MJ. Predictors of perceived breast cancer risk and the relation between perceived risk and breast cancer screening: a meta-analytic review. *Prev. Med.* 38(4), 388–402 (2004).

104. Robb KA, Miles A, Wardle J. Demographic and psychosocial factors associated with perceived risk for colorectal cancer. *Cancer Epidemiol. Biomarkers* 13(3), 366–372 (2004).

105. Pfeffer N. Screening for breast cancer: candidacy and compliance. *Soc. Sci. Med.* 58(1), 151–160 (2004).

106. Bikker AP, MacDonald S, Robb KA et al. Perceived colorectal cancer candidacy and the role of candidacy in colorectal cancer screening. *Health Risk Soc.* 21(7–8), 352–372 (2019).

107. Robb KA, Miles A, Wardle J. Perceived risk of colorectal cancer: sources of risk judgments. *Cancer Epidemiol. Biomarkers* 16(4), 694–702 (2007).

108. Marlow LaV, Chorley AJ, Haddrell J, Ferrer R, Waller J. Understanding the heterogeneity of cervical cancer screening non-participants: data from a national sample of British women. *Eur. J. Cancer* 80, 30–38 (2017).

109. Shang C, Beaver K, Campbell M. Social cultural influences on breast cancer views and breast health practices among Chinese women in the United Kingdom. *Cancer Nurs.* 38(5), 343–350 (2015).

110. Smith-Mcallen A, Fishbein M. Predictors of intentions to perform six cancer-related behaviours: roles for injunctive and descriptive norms. *Psychol. Health Med.* 13(4), 389–401 (2008).

111. Vrinten C, Waller J, Marlow LaV. Cancer stigma and cancer screening attendance: a population-based survey in England. *Lancet* 388, S109 (2016).

112. Quaife SL, Marlow LA, Mcewen A, Janes SM, Wardle J. Attitudes towards lung cancer screening in socioeconomically deprived and heavy smoking communities: informing screening communication. *Health Expect.* 20(4), 563–573 (2016).

113. Silvestri GA, Nietert PJ, Zoller J, Carter C, Bradford D. Attitudes towards screening for lung cancer among smokers and their non-smoking counterparts. *Thorax* 62(2), 126–130 (2007).

114. Cole AM, Jackson JE, Doescher M. Urban-rural disparities in colorectal cancer screening: cross-sectional analysis of 1998–2005 data from the Centers for Disease Control's Behavioral Risk Factor Surveillance Study. *Cancer Med.* 1(3), 350–356 (2012).

115. Jensen LF, Pedersen AF, Andersen B, Vedsted P. Social support and non-participation in breast cancer screening: a Danish cohort study. *J. Public Health* 38(2), 335–342 (2015).

116. Fallowfield LJ, Rodway A, Baum M. What are the psychological factors influencing attendance, non-attendance and re-attendance at a breast screening centre? *J. R. Soc. Med.* 83(9), 547–551 (1990).
118. Smith SG, McGregor LM, Raine R, Wardle J, Von Wagner C, Robb KA. Inequalities in cancer screening participation: examining differences in perceived benefits and barriers. *Psychon. Bull. Rev.* 25(10), 1168–1174 (2016).

119. Power E, Van Jaarsveld CH, Mccaferry K, Miles A, Atkin W, Wardle J. Understanding intentions and action in colorectal cancer screening. *Ann. Behav. Med.* 35(3), 285–294 (2008).

120. Allgood PC, Maxwell AJ, Hudson S et al. A randomised trial of the effect of postal reminders on attendance for breast screening. *Br. J. Cancer* 114(2), 171–176 (2016).

121. Kerrison RS, Shulda H, Cunningham D, Oyebode O, Friedman E. Text-message reminders increase uptake of routine breast screening appointments: a randomised controlled trial in a hard-to-reach population. *Br. J. Cancer* 112(6), 1005–1010 (2015).

122. Eaker S, Adami HO, Granath F, Wilander E, Sparén P. A large population-based randomized controlled trial to increase attendance at screening for cervical cancer. *Cancer Epidemiol. Biomarkers Prev.* 13(3), 346–354 (2004).

123. Hirst Y, Skrobanski H, Kerrison RS. Text-message reminders in colorectal cancer screening (TRICCS): a randomised controlled trial. *Br. J. Cancer* 116(11), 1408–1414 (2017).

124. Uy C, Lopez J, Trinh-Shevrin C, Kwon SC, Sherman SE, Liang PS. Text messaging interventions on cancer screening rates: a systematic review. *J. Med. Internet Res.* 19(8), e296 (2017).

125. Rat C, Latour C, Rousseau R et al. Interventions to increase uptake of faecal tests for colorectal cancer screening: a systematic review. *Eur. J. Cancer Prev.* 27(3), (2018).

126. Kirchener HC, Gittins M, Rivero-Arias O et al. A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC). *Health Technol. Assess.* 20(68), 1–138 (2016).

127. Wardle J, Von Wagner C, Kralj-Hans I et al. Effects of evidence-based strategies to reduce the socioeconomic gradient of uptake in the English NHS bowel cancer screening programme (ASCEND): four cluster-randomised controlled trials. *Lancet* 387(10020), 751–759 (2016).

128. Shea S, Dumouchel W, Bahamonde L. A meta-analysis of 16 randomized controlled trials to evaluate computer-based clinical reminder systems for preventive care in the ambulatory setting. *J. Am. Med. Inform. Assoc.* 3(6), 399–409 (1996).

129. Duffy SW, Myles JP, Maroni R, Mohammad A. Rapid review of evaluation of interventions to improve participation in cancer screening services. *J. Med. Screen.* 24(3), 127–145 (2017).

130. Everett T, Bryant A, Griffin MF, Martin-Hirsch PP, Forbes CA, Jepson RG. Interventions targeted at women to encourage the uptake of cervical screening. *Cochrane Database Syst. Rev.* 2011(5), CD002834 (2011).

131. Allgood PC, Maroni R, Hudson S et al. Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial. *Lancet Oncol.* 18(7), 972–980 (2017).

132. Offman J, Wilson M, Lamont M et al. A randomised trial of weekend and evening breast screening appointments. *Br. J. Cancer* 109(3), 597–602 (2013).

133. Chambers JA, Callander AS, Grangeret R, O’carroll RE. Attitudes towards the faecal occult blood test (FOBT) versus the faecal immunochemical test (FIT) for colorectal cancer screening: perceived ease of completion and disgust. *BMC Cancer* 16(1), 96 (2016).

134. Public Health Scotland. Scottish bowel screening programme (2020). www.isdscotland.org/Health-Topics/Cancer/Bowel-Screening/

135. Nelson EJ, Maynard BR, Loux T, Fatla J, Gordon R, Arnold LD. The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis. *Sex. Transm. Infect.* 93(1), 56–61 (2017).

136. Wakefield MA, Loken B, Hornik RC. Use of mass media campaigns to change health behaviour. *Health Psychol. Rev.* 1, 194–243 (2007).

137. Mullins R, Wakefield M, Broun K. Encouraging the right women to attend for cervical cancer screening: results from a targeted television campaign in Victoria, Australia. *Health Educ. Res.* 23(3), 477–486 (2008).

138. Durkin S, Broun K, Guerin N, Morley B, Wakefield M. Impact of a mass media campaign on participation in the Australian bowel cancer screening program. *J. Med. Screen.* 27(1), 18–24 (2019).

139. Lancucki L, Sasieni P, Patnick J, Day TJ, Vessey MP. The impact of Jade Goody’s diagnosis and death on the NHS cervical screening programme. *Br. J. Cancer* 112(6), 1005–1010 (2015).

140. Tsipa A, O’connor DB, Branley-Bell D et al. Promoting colorectal cancer screening: a systematic review and meta-analysis of randomised controlled trials of interventions to increase uptake. *Health Psychol. Rev.* doi:10.1080/17437199.2020.1760726 1–24 (2020) (Epub ahead of print).

141. Wardle J, Williamson S, Mccaffery K et al. Increasing attendance at colorectal cancer screening: testing the efficacy of a mailed, psychosocial intervention in a community sample of older adults. *Health Psychol.* 22(1), 99–105 (2003).

142. Hewitson P, Ward AM, Heneghan C, Halloran SP, Mant D. Primary care endorsement letter and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial randomised trial. *Br. J. Cancer* 105(4), 475–480 (2011).

143. Arnold CL, Rademaker A, Wolf MS et al. Final results of a 3-year literacy-informed intervention to promote annual faecal occult blood test screening. *J. Community Health* 41(4), 724–731 (2016).

144. Brotherstone H, Miles A, Robb KA, Atkin W, Wardle J. The impact of illustrations on public understanding of the aim of cancer screening. *Patient Educ. Couns.* 63(3), 328–355 (2006).
145. National Health Service Digital. New social media techniques used to boost cancer screening rates (2020). https://digital.nhs.uk/news-and-events/latest-news/new-social-media-techniques-used-to-boost-cancer-screening-rates

146. Zajac IT, Whibley AH, Cole SR et al. Endorsement by the primary care practitioner consistently improves participation in screening for colorectal cancer: a longitudinal analysis. J. Med. Screen. 17(1), 19–24 (2010).

147. Raine R, Duffy SW, Wardle J et al. Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening. Br. J. Cancer 114(3), 321–326 (2016).

148. Giorgi D, Giordano L, Senore C et al. General practitioners and mammographic screening uptake: influence of different modalities of general practitioner participation. Working Group. Tumori 86(2), 124–129 (2000).

149. Eilbert KW, Carroll K, Peach J, Khatooon S, Basnett I, McCulloch N. Approaches to improving breast screening uptake: evidence and experience from Tower Hamlets. Br. J. Cancer 101(Suppl. 2), S64–S67 (2009).

150. De Nooijer DP, De Waart FG, Van Leeuwen AW, Spijker WW. Participation in the Dutch national screening programme for uterine cervix cancer higher after invitation by a general practitioner, especially in groups with a traditional low level of attendance. Ned. Tijdschr. Geneeskd 149(42), 2339–2343 (2005).

151. Hermens RP, Tacken MA, Hulscher ME, Braspenninck JC, Grol RP. Attendance to cervical cancer screening in family practices in the Netherlands. Prev. Med. 30(1), 35–42 (2000).

152. Manning M, Lucas T, Davis SN, Valdimarsdottir HB, Thompson H. Editor’s choice: deliberative and non-deliberative effects of descriptive and injunctive norms on cancer screening behaviors among African Americans. Psychol. Health 35(7), 774–794 (2020).

153. O’keefee DJ, Jensen JD. The relative persuasiveness of gain-framed and loss-framed messages for encouraging disease prevention behaviors: a meta-analytic review. J. Health Commun. 12(7), 623–644 (2007).

154. Ferrer RA, Klein WMP, Zajac LE, Land SR, Ling BS. An affective booster moderates the effect of gain- and loss-framed messages on behavioral intentions for colorectal cancer screening. J. Behav. Med. 35(4), 452–461 (2012).

155. O’carroll RE, Chambers JA, Brownlee L, Libby G, Steele RJ. Anticipated regret to increase uptake of colorectal cancer screening (ARTICS): a randomised controlled trial. Soc. Sci. Med. 142, 118–127 (2015).

156. Sandberg T, Conner M. A mere measurement effect for anticipated regret: Impacts on cervical screening attendance. Br. J. Soc. Psychol. 48(2), 221–236 (2009).

157. Lo SH, Good A, Sheeran P et al. Preformulated implementation intentions to promote colorectal cancer screening: a cluster-randomized trial. Health Psychol. 33(9), 998–1002 (2014).

158. Rutter DR, Steadman L, Quine L. An implementation intentions intervention to increase uptake of mammography. Ann. Behav. Med. 32(2), 127–134 (2006).

159. O’keefee DJ, Jensen JD. The relative persuasiveness of gain-framed and loss-framed messages for encouraging disease prevention behaviors: a meta-analytic review. J. Health Commun. 12(7), 623–644 (2007).

160. Gollwitzer PM, Sheeran P. Implementation intentions and goal achievement: a meta-analysis of effects and processes. In: Advances in Experimental Social Psychology. Academic Press, 38, 69–119 (2006).

161. Baker DW, Brown T, Buchanan DR et al. Comparative effectiveness of a multifaceted intervention to improve adherence to annual colorectal cancer screening in community health centers: a randomized clinical trial. JAMA Intern. Med. 174(8), 1235–1241 (2014).

162. Sarma EA, Silver MI, Kobrin SC, Marcus PM, Ferrer RA. Cancer screening: health impact, prevalence, correlates, and interventions. Psychol. Health 34(9), 1036–1072 (2019).

163. Richards M. Independent review of adult screening programmes in England (2019). https://www.england.nhs.uk/wp-content/uploads/2019/02/report-of-the-independent-review-of-adult-screening-programme-in-england.pdf

164. Lebrett MB, Balata H, Evison M et al. Analysis of lung cancer risk model (PLCO2012 and LLP,α) performance in a community-based lung cancer screening programme. Thorax 75(8), 661–668 (2020).

165. Sullivan FM, Mair FS, Anderson W et al. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. Eur. Respir. J. 57(1), 2000670 (2021).

166. Smith SK, Trevena L, Simpson JM, Barratt A, Nutbeam D, McCaffrey KJ. A decision aid to support informed choices about bowel cancer screening among adults with low education: randomised controlled trial. BMJ 341, c5370 (2010).

167. Hersch J, Barratt A, Jansen J et al. Use of a decision aid including information on overdetection to support informed choice about breast cancer screening: a randomised controlled trial. Lancet 385(9978), 1642–1652 (2015).

168. Winter K. Putting the fear back into fear appeals: the extended parallel process model. Commun. Mongr. 59(4), 329–349 (1992).

169. Rivera MP, Katki HA, Tanner NT et al. Addressing disparities in lung cancer screening eligibility and healthcare access. An official American Thoracic Society statement. Am. J. Respir. Crit. Care Med. 202(7), e95–e112 (2020).

170. Quaife SL, Ruparel M, Dickson JL et al. Lung Screen Uptake Trial (LSUT): randomized controlled clinical trial testing targeted invitation materials. Am. J. Respir. Crit. Care Med. 201(8), 965–975 (2020).

171. Zeliadt SB, Heffner JL, Sayre G et al. Attitudes and perceptions about smoking cessation in the context of lung cancer screening. JAMA Intern. Med. 175(9), 1530–1537 (2015).
172. Douglas E, Waller J, Duffy SW, Wardle J. Socioeconomic inequalities in breast and cervical screening coverage in England: are we closing the gap? J. Med. Screen. 23(2), 98–103 (2016).

173. Barley EA, Borschmann RD, Walters P, Tylee A. Interventions to encourage uptake of cancer screening for people with severe mental illness. Cochrane Database Syst. Rev. 9(9), CD009641 (2016).